Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it dosed the first patient in Part B of a …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, announced that its Clinical Trial Application for ARC-520, its clinical candidate for …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, announced the United States Food and Drug Administration (FDA) has granted ARC-AAT …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2015 second quarter ended March 31, …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today presented data at IBC’s 17th Annual TIDES Conference in San Diego on …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, announced that it completed dosing healthy volunteers and will begin dosing patients …
Arrowhead Research Corp (NASDAQ:ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, announced that the United States Food and Drug Administration (FDA) informed the …
Chicago IL / Research Report Wire / February 27th, 2015 / Institutional Analyst Inc.(IA) announced today it released the its Top 20 Biotech …
Zacks analyst Grant Zeng was out pounding the table on Arrowhead Research Corp. (NASDAQ:ARWR), reiterating an Outperform rating and a $15 price target, which represents a …
